Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report

A 46-year-old man underwent right partial nephrectomy for type 2 papillary renal cell carcinoma (PRCC) in 2011. Lung metastasis and lymph node (LN) metastases around the inferior vena cave appeared in 2012. A right radical nephrectomy and extensive LN dissection was performed and the resection of lu...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2021-04, Vol.14 (4), p.71-71, Article 71
Main Authors: Arai, Yuichi, Kitamura, Yosuke, Miyai, Kosuke, Hatanaka, Mina, Hashimoto, Hirofumi, Horiguchi, Akio, Ito, Keiichi
Format: Article
Language:English
Subjects:
Case reports
Clinical trials
Cytokines
Disease control
Dissection
Drug dosages
Drug withdrawal
Inhibitor drugs
Kidney cancer
Medical prognosis
Metastasis
Oncology
Patients
Performance evaluation
Radiation therapy
Schedules
Targeted cancer therapy
Vertebrae
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 46-year-old man underwent right partial nephrectomy for type 2 papillary renal cell carcinoma (PRCC) in 2011. Lung metastasis and lymph node (LN) metastases around the inferior vena cave appeared in 2012. A right radical nephrectomy and extensive LN dissection was performed and the resection of lung metastasis was performed one month after the nephrectomy. Mediastinal LN metastases occurred in 2013, and resection of the affected LNs was performed. Sunitinib and zoledronic acid was started in 2014 because mediastinal LN swelling and multiple bone metastases appeared. Sunitinib treatment was stopped soon after due to adverse events and axitinib treatment was started. Axitinib was effective and the patient had stable disease for 30 months. Adverse events were successfully controlled by dose reduction and periodic drug withdrawal schedules (for example, 5 days on, 2 days off). Axitinib was further continued for 19 months as the metastatic lesions had progressed slowly. Temsirolimus treatment was started in 2019, but it was stopped after three cycles due to interstitial pneumonia. The patient died 80 months after the initial recurrence. Using multidisciplinary treatment, durable disease control was achieved in a patient with metastatic type 2 PRCC.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2021.2233